ANN ARBOR, MI / ACCESSWIRE / January 10, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting a conference call on Wednesday, January 17, 2024 at 4:30 p.m. ET.
Management will provide a business update, including preliminary 2023 revenue and cash position, as well as other operational highlights during the call. In addition, the Company will discuss the upcoming Share Consolidation ("reverse stock split") and other matters related to a Special Virtual-Only Meeting of Shareholders to be held on February 28, 2024, at 1:00 p.m. ET.
A question-and-answer session will follow management's prepared remarks.
Event: Zomedica Business Update Call
Date: Wednesday, January 17, 2024
Time: 4:30 p.m. Eastern Time
Live Call: 1-877-407-0789 (U.S. Toll Free) or 1-201-689-8562 (International)
Webcast: Zomedica Business Update Webcast
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Wednesday, January 31, 2024, at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13743242.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit zomedica.com.
Follow Zomedica
Investor Contact:
Zomedica Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-734-369-2555
| Last Trade: | US$0.05 |
| Daily Volume: | 587,432 |
February 06, 2025 December 23, 2024 November 27, 2024 November 14, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
